ArticleMolecular imaging and radionuclide therapy2024
Diagnostic Performance of FAPI PET/CT vs.
Article in Molecular imaging and radionuclide therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Revolutionizing cancer diagnosis and dose biodistribution: a meta-analysis of [68ga] FAPI- 46 vs. [18f] FDG imaging.Systematic reviews · 2025Pooled it
- Machine learning for the prediction of diabetes-related amputation: a systematic review and meta-analysis of diagnostic test accuracy.Clinical and experimental medicine · 2025Pooled it
- Same-day dual-tracer PET/CT imaging with [Annals of nuclear medicine · 2025Trial
- Head-to-head study of [BMC cancer · 2024Trial
- Glypican-3-targeted bioconjugates for hepatocellular carcinoma: design, engineering, and translational applications.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- FAPI: a solution to all, what about NENs?EJNMMI reports · 2026Review
- Is There an Added Value of Dual-Time-Point [Cancers · 2026Article
- The predictive value ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Comparative evaluation of [European journal of nuclear medicine and molecular imaging · 2026Article
- The comparative diagnostic and therapeutic application value of FAPI PET/CT andFrontiers in oncology · 2026Review
- In Vitro Characterization of the Published Glypican-3-Targeting Peptide TJ12P2 Reveals a Lack of Specificity and Potency.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Primary liver tumors constitute one of the most common tumors. These are aggressive tumors with poor survival. Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), most commonly used functional imaging, shows limited tracer retention and poor tumor to background ratios (TBR). Novel Methods: Literature available on head to head comparison of diagnostic accuracy of Results: Pooled sensitivity and specificity of FAPI PET/CT and Conclusion: Overall, FAPI PET/CT showed higher sensitivity for detection of liver tumors with better SUV
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.